Bharat Biotech's Strengths

• First bio-pharma company in the country to manufacture injectables (Small Volume Parentals) for the Korean market
• First to manufacture a preservative-free vaccine for regulated markets
• State-of-the-art manufacturing plants meeting stringent standards laid down by internationally recognised institutions such as USFDA, UKMCA and WHO

Contract Manufacturing

• Bharat Biotech International Limited set a precedent in this emerging area with the manufacture of HibTITER (Haemophilus Influenzae b Conjugate Vaccine) for Wyeth Lederle Limited. This was the first time that a vaccine was moved out of USA for manufacturing in India
• BBIL is also manufacturing a cancer therapeutic for Agenix Inc. USA

Manufacturing Strengths

• Wide range of manufacturing capabilities on an expanding scale to top-of-the-line multinational and Indian companies
• Production capabilities extending to vaccines and biotherapeutics
• State-of-the-art manufacturing plants meeting stringent standards laid down by internationally recognised institutions such as USFDA, UKMCA and WHO

Audits

• Manufacturing facilities audited and certified as conforming to WHO-GMP
• Manufacturing facilities audited by international regulatory authorities, independent international audit agencies and institutional partners